U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C16H17N3O7S2
Molecular Weight 427.452
Optical Activity UNSPECIFIED
Defined Stereocenters 2 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of CEFOXITIN

SMILES

[H][C@]12SCC(COC(N)=O)=C(N1C(=O)[C@]2(NC(=O)CC3=CC=CS3)OC)C(O)=O

InChI

InChIKey=WZOZEZRFJCJXNZ-ZBFHGGJFSA-N
InChI=1S/C16H17N3O7S2/c1-25-16(18-10(20)5-9-3-2-4-27-9)13(23)19-11(12(21)22)8(6-26-15(17)24)7-28-14(16)19/h2-4,14H,5-7H2,1H3,(H2,17,24)(H,18,20)(H,21,22)/t14-,16+/m1/s1

HIDE SMILES / InChI
Molecular Formula C16H17N3O7S2
Molecular Weight 427.452
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 2 / 2
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment: Description was created based on several sources, including https://www.drugs.com/pro/cefoxitin.html

Cefoxitin is a cephamycin antibiotic often grouped with the second-generation cephalosporins. It is active against a broad range of gram-negative bacteria including anaerobes. The methoxy group in the 7a position provides cefoxitin with a high degree of stability in the presence of beta-lactamases, both penicillinases and cephalosporinases, of gram-negative bacteria. The bactericidal action of cefoxitin results from inhibition of cell wall synthesis.

CNS Activity

Originator

Approval Year

1978
84
Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: Escherichia coli growth
Inhibitor
8228
Target ID: Klebsiella pneumoniae growth
Inhibitor
8228
D-alanyl-D-alanine carboxypeptidase DacC
3
Target ID: P08506
Gene ID: 945455.0
Gene Symbol: dacC
Target Organism: Escherichia coli (strain K12)
Inhibitor
8228
D-alanyl-D-alanine carboxypeptidase DacA
4
Target ID: P0AEB2
Gene ID: 945222.0
Gene Symbol: dacA
Target Organism: Escherichia coli (strain K12)
Inhibitor
8228
D-alanyl-D-alanine endopeptidase
2
Target ID: P0AFI5
Gene ID: 946662.0
Gene Symbol: pbpG
Target Organism: Escherichia coli (strain K12)
Inhibitor
8228
Penicillin-binding protein 1B
21
Target ID: P02919
Gene ID: 944843.0
Gene Symbol: mrcB
Target Organism: Escherichia coli (strain K12)
Inhibitor
8228
Penicillin-binding protein 2B
10
Target ID: P0A3M6
Gene ID: 933948.0
Gene Symbol: penA
Target Organism: Streptococcus pneumoniae (strain ATCC BAA-255 / R6)
Inhibitor
8228
 8.0 nM [IC50]
Penicillin-binding protein 1A
45
Target ID: Q8DR59
Gene ID: 934791.0
Gene Symbol: pbpA
Target Organism: Streptococcus pneumoniae (strain ATCC BAA-255 / R6)
Inhibitor
8228
 6.8 nM [IC50]
penicillin-binding protein 2A
2
Target ID: 933569.0
Gene Symbol: pbp2a
Inhibitor
8228
 2.4 nM [IC50]
penicillin-binding protein 1B
2
Target ID: 934893.0
Gene Symbol: pbp1b
Inhibitor
8228
 0.145 nM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
Approved
8360
Cefoxitin

Approved Use

Cefoxitin for Injection, USP is indicated for the treatment of serious infections caused by susceptible strains of the designated microorganisms in the diseases listed below. (1) Lower respiratory tract infections, including pneumonia and lung abscess, caused by Streptococcus pneumoniae, other streptococci (excluding enterococci, e.g., Enterococcus faecalis [formerly Streptococcus faecalis]), Staphylococcus aureus (including penicillinase-producing strains), Escherichia coli, Klebsiella species, Haemophilus influenzae, and Bacteroides species. (2) Urinary tract infections caused by Escherichia coli, Klebsiella species, Proteus mirabilis, Morganella morganii, Proteus vulgaris and Providencia species (including P. rettgeri). (3) Intra-abdominal infections, including peritonitis and intra-abdominal abscess, caused by Escherichia coli, Klebsiella species, Bacteroides species including Bacteroides fragilis, and Clostridium species. (4) Gynecological infections, including endometritis, pelvic cellulitis, and pelvic inflammatory disease caused by Escherichia coli, Neisseria gonorrhoeae (including penicillinase-producing strains), Bacteroides species including B. fragilis, Clostridium species, Peptococcus niger, Peptostreptococcus species and Streptococcus agalactiae. Cefoxitin for injection, like cephalosporins, has no activity against Chlamydia trachomatis. Therefore, when Cefoxitin for injection is used in the treatment of patients with pelvic inflammatory disease and C. trachomatis is one of the suspected pathogens, appropriate anti-chlamydial coverage should be added. (5) Septicemia caused by Streptococcus pneumoniae, Staphylococcus aureus (including penicillinase-producing strains), Escherichia coli, Klebsiella species, and Bacteroides species including B. fragilis. (6) Bone and joint infections caused by Staphylococcus aureus (including penicillinase-producing strains). (7) Skin and skin structure infections caused by Staphylococcus aureus (including penicillinase-producing strains), Staphylococcus epidermidis, Streptococcus pyogenes and other streptococci (excluding enterococci e.g., Enterococcus faecalis [formerly Streptococcus faecalis]), Escherichia coli, Proteus mirabilis, Klebsiella species, Bacteroides species including B. fragilis, Clostridium species, Peptococcus niger, and Peptostreptococcus species.

Launch Date

1.26826565E12
Curative
Approved
8360
Cefoxitin

Approved Use

Cefoxitin for Injection, USP is indicated for the treatment of serious infections caused by susceptible strains of the designated microorganisms in the diseases listed below. (1) Lower respiratory tract infections, including pneumonia and lung abscess, caused by Streptococcus pneumoniae, other streptococci (excluding enterococci, e.g., Enterococcus faecalis [formerly Streptococcus faecalis]), Staphylococcus aureus (including penicillinase-producing strains), Escherichia coli, Klebsiella species, Haemophilus influenzae, and Bacteroides species. (2) Urinary tract infections caused by Escherichia coli, Klebsiella species, Proteus mirabilis, Morganella morganii, Proteus vulgaris and Providencia species (including P. rettgeri). (3) Intra-abdominal infections, including peritonitis and intra-abdominal abscess, caused by Escherichia coli, Klebsiella species, Bacteroides species including Bacteroides fragilis, and Clostridium species. (4) Gynecological infections, including endometritis, pelvic cellulitis, and pelvic inflammatory disease caused by Escherichia coli, Neisseria gonorrhoeae (including penicillinase-producing strains), Bacteroides species including B. fragilis, Clostridium species, Peptococcus niger, Peptostreptococcus species and Streptococcus agalactiae. Cefoxitin for injection, like cephalosporins, has no activity against Chlamydia trachomatis. Therefore, when Cefoxitin for injection is used in the treatment of patients with pelvic inflammatory disease and C. trachomatis is one of the suspected pathogens, appropriate anti-chlamydial coverage should be added. (5) Septicemia caused by Streptococcus pneumoniae, Staphylococcus aureus (including penicillinase-producing strains), Escherichia coli, Klebsiella species, and Bacteroides species including B. fragilis. (6) Bone and joint infections caused by Staphylococcus aureus (including penicillinase-producing strains). (7) Skin and skin structure infections caused by Staphylococcus aureus (including penicillinase-producing strains), Staphylococcus epidermidis, Streptococcus pyogenes and other streptococci (excluding enterococci e.g., Enterococcus faecalis [formerly Streptococcus faecalis]), Escherichia coli, Proteus mirabilis, Klebsiella species, Bacteroides species including B. fragilis, Clostridium species, Peptococcus niger, and Peptostreptococcus species.

Launch Date

1.26826565E12
Curative
Approved
8360
Cefoxitin

Approved Use

Cefoxitin for Injection, USP is indicated for the treatment of serious infections caused by susceptible strains of the designated microorganisms in the diseases listed below. (1) Lower respiratory tract infections, including pneumonia and lung abscess, caused by Streptococcus pneumoniae, other streptococci (excluding enterococci, e.g., Enterococcus faecalis [formerly Streptococcus faecalis]), Staphylococcus aureus (including penicillinase-producing strains), Escherichia coli, Klebsiella species, Haemophilus influenzae, and Bacteroides species. (2) Urinary tract infections caused by Escherichia coli, Klebsiella species, Proteus mirabilis, Morganella morganii, Proteus vulgaris and Providencia species (including P. rettgeri). (3) Intra-abdominal infections, including peritonitis and intra-abdominal abscess, caused by Escherichia coli, Klebsiella species, Bacteroides species including Bacteroides fragilis, and Clostridium species. (4) Gynecological infections, including endometritis, pelvic cellulitis, and pelvic inflammatory disease caused by Escherichia coli, Neisseria gonorrhoeae (including penicillinase-producing strains), Bacteroides species including B. fragilis, Clostridium species, Peptococcus niger, Peptostreptococcus species and Streptococcus agalactiae. Cefoxitin for injection, like cephalosporins, has no activity against Chlamydia trachomatis. Therefore, when Cefoxitin for injection is used in the treatment of patients with pelvic inflammatory disease and C. trachomatis is one of the suspected pathogens, appropriate anti-chlamydial coverage should be added. (5) Septicemia caused by Streptococcus pneumoniae, Staphylococcus aureus (including penicillinase-producing strains), Escherichia coli, Klebsiella species, and Bacteroides species including B. fragilis. (6) Bone and joint infections caused by Staphylococcus aureus (including penicillinase-producing strains). (7) Skin and skin structure infections caused by Staphylococcus aureus (including penicillinase-producing strains), Staphylococcus epidermidis, Streptococcus pyogenes and other streptococci (excluding enterococci e.g., Enterococcus faecalis [formerly Streptococcus faecalis]), Escherichia coli, Proteus mirabilis, Klebsiella species, Bacteroides species including B. fragilis, Clostridium species, Peptococcus niger, and Peptostreptococcus species.

Launch Date

1.26826565E12
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
24 μg/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/318227/
1 g single, intramuscular
dose: 1 g
route of administration: Intramuscular
experiment type: SINGLE
co-administered:
CEFOXITIN plasma
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
33.5 μg × h/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/318227/
1 g single, intramuscular
dose: 1 g
route of administration: Intramuscular
experiment type: SINGLE
co-administered:
CEFOXITIN plasma
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
0.67 h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/318227/
1 g single, intramuscular
dose: 1 g
route of administration: Intramuscular
experiment type: SINGLE
co-administered:
CEFOXITIN plasma
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
27%
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/318227/
1 g single, intramuscular
dose: 1 g
route of administration: Intramuscular
experiment type: SINGLE
co-administered:
CEFOXITIN plasma
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
2 g single, intramuscular
Dose: 2 g
Route: intramuscular
Route: single
Dose: 2 g
Sources:
https://pubmed.ncbi.nlm.nih.gov/3578148
unhealthy, 17 years
n = 1
Health Status: unhealthy
Age Group: 17 years
Sex: F
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/3578148
Disc. AE: Hoigne's syndrome...
AEs leading to
discontinuation/dose reduction:
Hoigne's syndrome (1 patient)
Sources:
https://pubmed.ncbi.nlm.nih.gov/3578148
12 g 1 times / day multiple, intravenous
Highest studied dose
Dose: 12 g, 1 times / day
Route: intravenous
Route: multiple
Dose: 12 g, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/318219
unhealthy, 22 years
n = 1
Health Status: unhealthy
Condition: bacterial endocarditis
Age Group: 22 years
Sex: M
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/318219
Sources:
https://pubmed.ncbi.nlm.nih.gov/318219
2 g 3 times / day multiple, intravenous
Dose: 2 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 2 g, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/21042010
unhealthy, 45 years
n = 1
Health Status: unhealthy
Age Group: 45 years
Sex: F
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/21042010
Disc. AE: Hemolytic anemia...
AEs leading to
discontinuation/dose reduction:
Hemolytic anemia (1 patient)
Sources:
https://pubmed.ncbi.nlm.nih.gov/21042010
1 g 4 times / day multiple, intravenous
Dose: 1 g, 4 times / day
Route: intravenous
Route: multiple
Dose: 1 g, 4 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/6641504
unhealthy, 77 years
n = 1
Health Status: unhealthy
Condition: peritonitis
Age Group: 77 years
Sex: M
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/6641504
Disc. AE: Hemolytic anemia, Pancytopenia...
AEs leading to
discontinuation/dose reduction:
Hemolytic anemia (1 patient)
Pancytopenia (1 patient)
Sources:
https://pubmed.ncbi.nlm.nih.gov/6641504
AEs

AEs

AESignificanceDosePopulation
Hoigne's syndrome 1 patient
Disc. AE
2 g single, intramuscular
Dose: 2 g
Route: intramuscular
Route: single
Dose: 2 g
Sources:
https://pubmed.ncbi.nlm.nih.gov/3578148
unhealthy, 17 years
n = 1
Health Status: unhealthy
Age Group: 17 years
Sex: F
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/3578148
Hemolytic anemia 1 patient
Disc. AE
2 g 3 times / day multiple, intravenous
Dose: 2 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 2 g, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/21042010
unhealthy, 45 years
n = 1
Health Status: unhealthy
Age Group: 45 years
Sex: F
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/21042010
Hemolytic anemia 1 patient
Disc. AE
1 g 4 times / day multiple, intravenous
Dose: 1 g, 4 times / day
Route: intravenous
Route: multiple
Dose: 1 g, 4 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/6641504
unhealthy, 77 years
n = 1
Health Status: unhealthy
Condition: peritonitis
Age Group: 77 years
Sex: M
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/6641504
Pancytopenia 1 patient
Disc. AE
1 g 4 times / day multiple, intravenous
Dose: 1 g, 4 times / day
Route: intravenous
Route: multiple
Dose: 1 g, 4 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/6641504
unhealthy, 77 years
n = 1
Health Status: unhealthy
Condition: peritonitis
Age Group: 77 years
Sex: M
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/6641504
Sourcing

Sourcing

Vendor/AggregatorIDURL
ChEBI
CHEBI:209807
https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:209807
ChemicalBook
CB9490581
https://www.chemicalbook.com/ChemicalProductProperty_EN_CB9490581
MolPort
MolPort-006-127-091
https://www.molport.com/shop/molecule-link/MolPort-006-127-091
ZINC
ZINC000003830449
http://zinc15.docking.org/substances/ZINC000003830449
PubMed

PubMed

TitleDatePubMed
Ceftizoxime-induced hemolysis due to immune complexes: case report and determination of the epitope responsible for immune complex-mediated hemolysis.
1999 Mar
[Occurrence of beta-lactamase type ESBL and IBL in Pseudomonas aeruginosa rods].
2001
Antibacterial susceptibility of intestinal lactobacilli of healthy children.
2001
Occurrence of metronidazole and imipenem resistance among Bacteroides fragilis group clinical isolates in Hungary.
2001
Clinical features of patients with invasive Eikenella corrodens infections and microbiological characteristics of the causative isolates.
2001 Apr
[Staphylococcus aureus: new detection of intrinsic resistance using the diffusion method].
2001 Apr
A novel metallo-beta-lactamase, Mbl1b, produced by the environmental bacterium Caulobacter crescentus.
2001 Dec 14
Nosocomial bloodstream infection in pediatric patients: Siriraj Hospital, Bangkok; 1996-1999.
2001 Feb
A randomised controlled trial of antibiotic prophylaxis in elective caesarean delivery.
2001 Feb
Plasmid-mediated and inducible cephalosporinase DHA-2 from Klebsiella pneumoniae.
2001 Feb
Inactivation of Aeromonas hydrophila metallo-beta-lactamase by cephamycins and moxalactam.
2001 Jul
Detection of beta-lactamase-mediated resistance.
2001 Jul
Susceptibility of the Bacteroides fragilis group to newer quinolones and other standard anti-anaerobic agents.
2001 Jul
Antibiotic therapy in intra-abdominal infections--a review on randomised clinical trials.
2001 Jul 30
Antibacterial effect of antibiotic solution on cellular viability in canine veins.
2001 Jun
Antimicrobial resistance surveillance of bacteria in 1999 in Korea with a special reference to resistance of enterococci to vancomycin and gram-negative bacilli to third generation cephalosporin, imipenem, and fluoroquinolone.
2001 Jun
Antimicrobial resistance of Shigella sonnei in Korea during the last two decades.
2001 Mar
Cephalosporins in surgical prophylaxis.
2001 Nov
Molecular mechanisms of cefoxitin resistance in Escherichia coli from the Toronto area hospitals.
2001 Sep-Oct
Detection and typing of extended-spectrum beta-lactamases in clinical isolates of the family Enterobacteriaceae in a medical center in Turkey.
2001 Summer
Influence of failure of primary wound healing on subsequent recurrence of pilonidal sinus. combined prospective study and randomised controlled trial.
2002
Probing substrate binding to metallo-beta-lactamase L1 from Stenotrophomonas maltophilia by using site-directed mutagenesis.
2002
Cross-reactivity of cefotetan and ceftriaxone antibodies, associated with hemolytic anemia, with other: cephalosporins and penicillin.
2002 Aug
Increase in resistance to new fluoroquinolones from 1998 to 2001 in the Bacteroides fragilis group.
2002 Dec
Mycobacterium fortuitum complex endocarditis-case report and literature review.
2002 Feb
Crystal structures of the Bacillus licheniformis BS3 class A beta-lactamase and of the acyl-enzyme adduct formed with cefoxitin.
2002 Feb 12
Surgical prophylaxis in practice.
2002 Jan
Outbreak of multidrug-resistant Salmonella newport--United States, January-April 2002.
2002 Jun 28
Escherichia coli isolated from seafood: toxicity and plasmid profiles.
2002 Mar
A pathway-specific cell based screening system to detect bacterial cell wall inhibitors.
2002 Mar
The ACT-1 plasmid-encoded AmpC beta-lactamase is inducible: detection in a complex beta-lactamase background.
2002 Mar
[Genotypic exploration of a hospital neonatal outbreak due to Klebsiella pneumoniae producing extended-spectrum-betalactamase].
2002 May
Cefepime MIC as a predictor of the extended-spectrum beta-lactamase type in Klebsiella pneumoniae, Taiwan.
2002 May
Rapidly growing members of the genus Mycobacterium affecting dogs and cats.
2002 May-Jun
Comparison of screening methods for TEM- and SHV-derived extended-spectrum beta-lactamase detection.
2002 Nov
Further modification of the Hodge test to screen AmpC beta-lactamase (CMY-1)-producing strains of Escherichia coli and Klebsiella pneumoniae.
2002 Nov
[Trends in antimicrobial utilization in a university hospital, 1990-1996].
2002 Oct
Natural antibiotic susceptibility of Enterobacter spp., with special reference to Enterobacter aerogenes and Enterobacter intermedius strains.
2002 Oct
[Activity of 14 antimicrobials against Eikenella corrodens].
2002 Oct-Dec
Natural antibiotic susceptibility of Enterobacter amnigenus, Enterobacter cancerogenus, Enterobacter gergoviae and Enterobacter sakazakii strains.
2002 Sep
Selection of cefoxitin-resistant bacteroides thetaiotaomicron mutants and mechanisms involved in beta-lactam resistance.
2002 Sep 1
Automated ribotyping and pulsed-field gel electrophoresis for rapid identification of multidrug-resistant Salmonella serotype newport.
2003 Apr
Endometritis does not predict reproductive morbidity after pelvic inflammatory disease.
2003 Jan
Efficacy and safety of azithromycin as monotherapy or combined with metronidazole compared with two standard multidrug regimens for the treatment of acute pelvic inflammatory disease.
2003 Jan-Feb
Isolation of Escherichia coli O157:H7 from intact colon fecal samples of swine.
2003 Mar
Emergence of ceftriaxone-resistant Salmonella isolates and rapid spread of plasmid-encoded CMY-2-like cephalosporinase, Taiwan.
2003 Mar
Changes in sensitivity patterns to selected antibiotics in Clostridium difficile in geriatric in-patients over an 18-month period.
2003 Mar
A seven-year survey of Klebsiella pneumoniae producing TEM-24 extended-spectrum beta-lactamase in Nice University Hospital (1994-2000).
2003 May
Patents

Patents

07662955
10
JP2001500477A
122
JP2002541113A
46
JP2003515526A
461
JP2009541210A
78
JP2011528275A
453
JP4718445B2
36
JP4763957B2
85
JP4792032B2
111
JP4849764B2
75
JPH03279329A
9
JPS06143116A
2
JPS5583791A
2
JPS5711917A
2
JPS5942317A
6
JPS6143116A
2

Sample Use Guides

In Vivo Use Guide
Adults The usual adult dosage range is 1 gram to 2 grams every six to eight hours.
Route of Administration: Intravenous
In Vitro Use Guide
CEFOXITIN inhibited Mycobacterium fortuitum growth with MIC 32 ug/ml
Substance Class Chemical
Created
by admin
on Thu Jul 06 22:33:47 UTC 2023
Edited
by admin
on Thu Jul 06 22:33:47 UTC 2023
Record UNII
6OEV9DX57Y
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
CEFOXITIN
INN   MI   ORANGE BOOK   USAN   USP-RS   VANDF   WHO-DD  
INN   USAN  
Official Name English
J01DC01
Code English
(6R,7S)-3-(Hydroxymethyl)-7-methoxy-8-oxo-7-[2-(2-thienyl)acetamido]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid carbamate (ester)
Systematic Name English
CEFOXITIN [USAN]
Common Name English
Cefoxitin [WHO-DD]
Common Name English
CEFOXITIN [VANDF]
Common Name English
CEFOXITIN [USP-RS]
Common Name English
CEFOXITIN [ORANGE BOOK]
Common Name English
CEFOXITIN [MI]
Common Name English
cefoxitin [INN]
Common Name English
Classification Tree Code System Code
NDF-RT N0000011161
Created by admin on Thu Jul 06 22:33:47 UTC 2023 , Edited by admin on Thu Jul 06 22:33:47 UTC 2023
NDF-RT N0000011161
Created by admin on Thu Jul 06 22:33:47 UTC 2023 , Edited by admin on Thu Jul 06 22:33:47 UTC 2023
NDF-RT N0000011161
Created by admin on Thu Jul 06 22:33:47 UTC 2023 , Edited by admin on Thu Jul 06 22:33:47 UTC 2023
NDF-RT N0000011161
Created by admin on Thu Jul 06 22:33:47 UTC 2023 , Edited by admin on Thu Jul 06 22:33:47 UTC 2023
LIVERTOX NBK548666
Created by admin on Thu Jul 06 22:33:47 UTC 2023 , Edited by admin on Thu Jul 06 22:33:47 UTC 2023
NDF-RT N0000011161
Created by admin on Thu Jul 06 22:33:47 UTC 2023 , Edited by admin on Thu Jul 06 22:33:47 UTC 2023
NDF-RT N0000011161
Created by admin on Thu Jul 06 22:33:47 UTC 2023 , Edited by admin on Thu Jul 06 22:33:47 UTC 2023
WHO-VATC QJ01DC01
Created by admin on Thu Jul 06 22:33:47 UTC 2023 , Edited by admin on Thu Jul 06 22:33:47 UTC 2023
NDF-RT N0000011161
Created by admin on Thu Jul 06 22:33:47 UTC 2023 , Edited by admin on Thu Jul 06 22:33:47 UTC 2023
NDF-RT N0000175488
Created by admin on Thu Jul 06 22:33:47 UTC 2023 , Edited by admin on Thu Jul 06 22:33:47 UTC 2023
NDF-RT N0000011161
Created by admin on Thu Jul 06 22:33:47 UTC 2023 , Edited by admin on Thu Jul 06 22:33:47 UTC 2023
NDF-RT N0000011161
Created by admin on Thu Jul 06 22:33:47 UTC 2023 , Edited by admin on Thu Jul 06 22:33:47 UTC 2023
NCI_THESAURUS C357
Created by admin on Thu Jul 06 22:33:47 UTC 2023 , Edited by admin on Thu Jul 06 22:33:47 UTC 2023
NDF-RT N0000011161
Created by admin on Thu Jul 06 22:33:47 UTC 2023 , Edited by admin on Thu Jul 06 22:33:47 UTC 2023
LIVERTOX NBK547862
Created by admin on Thu Jul 06 22:33:47 UTC 2023 , Edited by admin on Thu Jul 06 22:33:47 UTC 2023
NDF-RT N0000011161
Created by admin on Thu Jul 06 22:33:47 UTC 2023 , Edited by admin on Thu Jul 06 22:33:47 UTC 2023
NDF-RT N0000011161
Created by admin on Thu Jul 06 22:33:47 UTC 2023 , Edited by admin on Thu Jul 06 22:33:47 UTC 2023
WHO-ATC J01DC01
Created by admin on Thu Jul 06 22:33:47 UTC 2023 , Edited by admin on Thu Jul 06 22:33:47 UTC 2023
Code System Code Type Description
ChEMBL
CHEMBL996
Created by admin on Thu Jul 06 22:33:47 UTC 2023 , Edited by admin on Thu Jul 06 22:33:47 UTC 2023
PRIMARY
MERCK INDEX
M3208
Created by admin on Thu Jul 06 22:33:47 UTC 2023 , Edited by admin on Thu Jul 06 22:33:47 UTC 2023
PRIMARY Merck Index
DRUG CENTRAL
550
Created by admin on Thu Jul 06 22:33:47 UTC 2023 , Edited by admin on Thu Jul 06 22:33:47 UTC 2023
PRIMARY
RS_ITEM_NUM
1098107
Created by admin on Thu Jul 06 22:33:47 UTC 2023 , Edited by admin on Thu Jul 06 22:33:47 UTC 2023
PRIMARY
ECHA (EC/EINECS)
252-641-2
Created by admin on Thu Jul 06 22:33:47 UTC 2023 , Edited by admin on Thu Jul 06 22:33:47 UTC 2023
PRIMARY
CAS
35607-66-0
Created by admin on Thu Jul 06 22:33:47 UTC 2023 , Edited by admin on Thu Jul 06 22:33:47 UTC 2023
PRIMARY
DAILYMED
6OEV9DX57Y
Created by admin on Thu Jul 06 22:33:47 UTC 2023 , Edited by admin on Thu Jul 06 22:33:47 UTC 2023
PRIMARY
WIKIPEDIA
CEFOXITIN
Created by admin on Thu Jul 06 22:33:47 UTC 2023 , Edited by admin on Thu Jul 06 22:33:47 UTC 2023
PRIMARY
LACTMED
Cefoxitin
Created by admin on Thu Jul 06 22:33:47 UTC 2023 , Edited by admin on Thu Jul 06 22:33:47 UTC 2023
PRIMARY
INN
3397
Created by admin on Thu Jul 06 22:33:47 UTC 2023 , Edited by admin on Thu Jul 06 22:33:47 UTC 2023
PRIMARY
EVMPD
SUB07409MIG
Created by admin on Thu Jul 06 22:33:47 UTC 2023 , Edited by admin on Thu Jul 06 22:33:47 UTC 2023
PRIMARY
CHEBI
209807
Created by admin on Thu Jul 06 22:33:47 UTC 2023 , Edited by admin on Thu Jul 06 22:33:47 UTC 2023
PRIMARY
MESH
D002440
Created by admin on Thu Jul 06 22:33:47 UTC 2023 , Edited by admin on Thu Jul 06 22:33:47 UTC 2023
PRIMARY
RXCUI
2189
Created by admin on Thu Jul 06 22:33:47 UTC 2023 , Edited by admin on Thu Jul 06 22:33:47 UTC 2023
PRIMARY RxNorm
FDA UNII
6OEV9DX57Y
Created by admin on Thu Jul 06 22:33:47 UTC 2023 , Edited by admin on Thu Jul 06 22:33:47 UTC 2023
PRIMARY
SMS_ID
100000081807
Created by admin on Thu Jul 06 22:33:47 UTC 2023 , Edited by admin on Thu Jul 06 22:33:47 UTC 2023
PRIMARY
DRUG BANK
DB01331
Created by admin on Thu Jul 06 22:33:47 UTC 2023 , Edited by admin on Thu Jul 06 22:33:47 UTC 2023
PRIMARY
NCI_THESAURUS
C61665
Created by admin on Thu Jul 06 22:33:47 UTC 2023 , Edited by admin on Thu Jul 06 22:33:47 UTC 2023
PRIMARY
EPA CompTox
DTXSID1022764
Created by admin on Thu Jul 06 22:33:47 UTC 2023 , Edited by admin on Thu Jul 06 22:33:47 UTC 2023
PRIMARY
PUBCHEM
441199
Created by admin on Thu Jul 06 22:33:47 UTC 2023 , Edited by admin on Thu Jul 06 22:33:47 UTC 2023
PRIMARY
Related Record Type Details
Structure of CEFOXITIN SODIUM
SALT/SOLVATE -> PARENT
PLASMA PROTEIN FRACTION (HUMAN)
BINDER->LIGAND
BINDING
Related Record Type Details
Structure of CEFOXITIN
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966